CADInvestor12 wrote: Lem, you’ve done some great research and have posted quality material, however you are over analyzing every little detail right now and in some cases are flat out wrong.
When MPL was profitable under Pat & Keith it was in spite of them, not because of them. Everyone was making money then, once the market soured, we saw how effective Keith and Pat were. Their initial focus on pharma was a great decision, but that’s simply where it ends, they are not operators. They created a great vision but are not the ones to execute it. Under their leadership, sales were going no where, operations were a disaster and overhead was incredibly bloated. Just look at the financials from before Pidduck. Do you really believe that PM & KS were capable of making the right tactical decisions to support MPL’s strategic vision? I sure as hell don’t. Get over your love affair.
Yes, I’m sure he was excited as should’ve been, Remidose shouldn’t be overlooked as a major catalyst as the pharma market develops. But that doesn’t mean squat, if you listen to their quarterly calls, you can hear the difference between Pidduck and Keith … one is clear, and concise, the other puts his foot in his mouth. Just look at the comment made about USC/ Keck .. he’s clueless. Moving to the board was an opportunity for him to save face and remove a redundancy.
I am going to say it one more time, MOST COMMERCIAL REAL ESTATE DEALS ARE NOT LISTED TO THE PUBLIC. The general public is not going to looking to add 30,000 sq ft facility in Hope, BC to their investment portfolio. Listings are sent to targeted buyers
How can you sit there and intelligently say that valuation is irrelevant & shopping the business at an all time low valuation is a good idea? Their assets alone are more than double the current M/C. They have zero negotiating leverage. API manufacturers are valued anywhere between 6x to 8x revenue, and given that we’re close to being able to access the US synthetic market + Generic Epidiolex + Remidose delivery system + Brazil Pharma + Clinical Trials expansion/ US pharma development. You want them to sell now? Quit the day drinking. Depending on how the approvals flow, this will sky rocket.